Maze Therapeutics, Inc. (MAZE) stock
MAZENasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$34.33−1.76 (-4.88%)
Close on Nov 13, 2026Market cap $1.91BP/E –Yield –
Maze Therapeutics cash
Cash and short-term investments held at the end of each period.
Maze Therapeutics's cash was $389.66M at Sep 30, 2026. For fiscal 2025 it was $341.92M, up 72.8% from the year before.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $341.92M | +72.8% |
| FY2024 | Dec 31, 2024 | $197.90M | +554.3% |
| FY2023 | Dec 31, 2023 | $30.25M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $389.66M | +1.5% |
| Q2 FY2026 | Jun 30, 2026 | $411.09M | +55.4% |
| Q1 FY2026 | Mar 31, 2026 | $362.90M | +23.3% |
| Q4 FY2025 | Dec 31, 2025 | $341.92M | +72.8% |
| Q3 FY2025 | Sep 30, 2025 | $383.90M | +156.6% |
| Q2 FY2025 | Jun 30, 2025 | $264.54M | +51.1% |
| Q1 FY2025 | Mar 31, 2025 | $294.37M | +880.5% |
| Q4 FY2024 | Dec 31, 2024 | $197.90M | +554.3% |
| Q3 FY2024 | Sep 30, 2024 | $149.61M | – |
| Q2 FY2024 | Jun 30, 2024 | $175.07M | – |
| Q1 FY2024 | Mar 31, 2024 | $30.02M | – |
| Q4 FY2023 | Dec 31, 2023 | $30.25M | – |
See a number that looks wrong?